EOLS - Evolus - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

EOLS is currently covered by 6 analysts with an average price target of $17.05. This is a potential upside of $10.98 (180.89%) from yesterday's end of day stock price of $6.07.

Evolus's activity chart (see below) currently has 102 price targets and 106 ratings on display. The stock rating distribution of EOLS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 37.99% with an average time for these price targets to be met of 191.17 days.

Highest price target for EOLS is $25, Lowest price target is $20, average price target is $23.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 06-Aug-2025. First documented stock forecast 14-May-2018.

Best performing analysts who are covering EOLS - Evolus:

Irina Rivkind Koffler Annabel Samimy Douglas Tsao Gregg Gilbert Vamil Divan Balaji Prasad Louise Chen Gregory Fraser Difei Yang Uy Ear

Currently out of the existing stock ratings of EOLS, 31 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Douglas Tsao (HC WAINWRIGHT)

Buy

$20

$13.93 (229.49%)

$27

4 days ago
(06-Aug-2025)

7/27 (25.93%)

$13.63 (213.97%)

437

Please subscribe to see the analyst performance score

Serge Belanger (NEEDHAM)

Buy

$22

$15.93 (262.44%)

$22

4 days ago
(06-Aug-2025)

0/13 (0%)

$15.63 (245.37%)

Please subscribe to see the analyst performance score

Balaji Prasad (BARCLAYS)

Buy

$25

$18.93 (311.86%)

$22

5 months 5 days ago
(05-Mar-2025)

7/10 (70%)

$10.83 (76.43%)

143

Please subscribe to see the analyst performance score

Louise Chen (CANTOR FITZGERALD)

Buy

10 months 25 days ago
(16-Sep-2024)

1/5 (20%)

$10.47 (109.86%)

Please subscribe to see the analyst performance score

Annabel Samimy (STIFEL)

Buy

$25

$18.93 (311.86%)

$23

1 years 5 months 2 days ago
(08-Mar-2024)

3/13 (23.08%)

$10.93 (77.68%)

104

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is EOLS (Evolus) average time for price targets to be met?

On average it took 191.17 days on average for the stock forecasts to be realized with a an average price target met ratio 37.99

Which analyst has the current highest performing score on EOLS (Evolus) with a proven track record?

IRINA RIVKIND KOFFLER

Which analyst has the most public recommendations on EOLS (Evolus)?

Irina Rivkind Koffler works at LIFESCI and has 4 price targets and 2 ratings on EOLS

Which analyst is the currently most bullish on EOLS (Evolus)?

Irina Koffler with highest potential upside - $21.38

Which analyst is the currently most reserved on EOLS (Evolus)?

Louise Chen with lowest potential downside - -$0

Evolus in the News

Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for

Haemonetics (HAE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company’s earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term...

Jeuveau shows fast onset and long duration in neurotoxin study

NEWPORT BEACH, Calif. – A landmark independent study published in JAMA Dermatology has directly compared four FDA-approved botulinum toxin products for treating glabellar lines, finding that Jeuveau (prabotulinumtoxinA-xvfs) demonstrated fast onset, strong peak effect, and long duration. The double-blind, randomized study conducted at the University of Pennsylvania involved 143 female participants aged 30 to 65...